TARS
Tarsus Pharmaceuticals, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Buy
+27/100
Last price
75.18
▲ 0.73 (0.97%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
74.45
Prev close
74.46
Day high
75.26
Day low
72.94
Volume
432.43K
Market cap
$3.47B
P/E (TTM)
—
52W range
53.89 – 91.53
Day trading desk
Gap from prior close
-0.01%
Prior close 74.46
VWAP
74.18
+1.35% from price
Relative volume
0.79×
Normal
Session range
3.17%
72.94 – 75.25
Position in range
97%
Near session high
ATR (14D)
2.64
3.51% of price
Prior day high
75.00
PDH
Prior day low
72.76
PDL
Bid / ask spread
—
Quote not published
Session volume
728.68K
Avg 926.24K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-3.36%
-5.3%
1M
-18.36%
-19.5%
3M
+9.42%
+4.9%
6M
+7.78%
-10.4%
YTD
-9.49%
-23.7%
1Y
+13.72%
-2.7%
3Y
+317.05%
+234.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on TARS open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-55.05K
Net selling
Buy transactions
10
47.39K shares
Sell transactions
10
102.44K shares
Net transactions
+20
Buys less sells
Sell : buy shares
2.2 : 1
Mixed
Insider-held shares
1.18M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 15, 26 | LINK WILLIAM J Director |
SELL | 12.50K | $979.74K | Direct |
| Sep 15, 26 | LINK WILLIAM J Director |
— | 201 | — | Direct |
| Sep 15, 26 | PYOTT DAVID E I Director |
— | 201 | — | Indirect |
| Sep 4, 26 | NEERVANNAN SESHADRI Chief Operating Officer |
SELL | 4.56K | $387.94K | Direct |
| Sep 4, 26 | AZAMIAN BOBAK R Chief Executive Officer |
SELL | 10.00K | $905.60K | Indirect |
| Sep 4, 26 | LIN ELIZABETH YEU Officer |
SELL | 13.95K | $1.22M | |
| Sep 2, 26 | AZAMIAN BOBAK R Chief Executive Officer |
SELL | 10.00K | $800.60K | Indirect |
| Sep 2, 26 | LIN ELIZABETH YEU Officer |
SELL | 11.58K | $897.99K | |
| Jun 17, 26 | AZAMIAN BOBAK R Chief Executive Officer |
SELL | 10.00K | $615.49K | Indirect |
| Jun 16, 26 | FARROW JEFFREY S Chief Financial Officer |
SELL | 14.40K | $877.44K | Direct |
| Jun 15, 26 | FARROW JEFFREY S Chief Financial Officer |
— | 27.88K | — | Direct |
| Jun 15, 26 | LINK WILLIAM J Director |
SELL | 12.50K | $776.50K | Direct |
| Jun 15, 26 | GOODRICH KATHERINE Director |
SELL | 2.95K | $183.38K | Direct |
| Jun 12, 26 | YARNO WENDY L Director |
— | 2.95K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
AZAMIAN BOBAK R |
Chief Executive Officer | — | Sale |
FARROW JEFFREY S |
Chief Financial Officer | 56.80K | Sale |
GOLDBERG ANDREW D |
Director | 19.65K | Conversion of Exercise of derivative security |
LIN ELIZABETH YEU |
Officer | — | Sale |
LINK WILLIAM J |
Director | 94.49K | Sale |
MOTTIWALA AZIZ |
Officer | 61.48K | Sale |
NEERVANNAN SESHADRI |
Chief Operating Officer | 79.01K | Sale |
WAHL BRYAN |
General Counsel | 63.96K | Sale |
WHITFIELD DIANNE C |
Officer | 35.03K | Sale |
YARNO WENDY L |
Director | 16.65K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$3.47B
Enterprise value$2.89B
Revenue (TTM)$606.33M
Gross profit$501.26M
EBITDA$-46.20M
Net income$-46.48M
EPS (TTM)$-1.08
Free cash flow$67.47M
Total cash$449.69M
Total debt$88.81M
Book value / share$8.01
Shares outstanding46.79M
Float32.74M
Short % of float13.50%
Dividend yield0.00%
Beta (5Y)0.45
Valuation & profitability ratios
Trailing P/E—
Forward P/E-205.86
PEG ratio—
Price / sales—
Price / book9.25
EV / revenue4.77
EV / EBITDA-62.59
Gross margin82.67%
Operating margin-11.45%
Profit margin-7.66%
Return on equity-13.68%
Return on assets-5.49%
Debt / equity25.61
Current ratio3.20
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $451.36M | $182.95M | $17.45M | $25.82M | +146.7% |
| Operating revenue | $451.36M | $182.95M | $17.45M | $25.82M | +146.7% |
| Cost of revenue | $30.68M | $12.83M | $1.59M | $955.00K | +139.2% |
| Gross profit | $420.68M | $170.13M | $15.85M | $24.86M | +147.3% |
| Research & development | $64.32M | $53.39M | $50.31M | $42.62M | +20.5% |
| Selling, general & admin | $427.32M | $237.31M | $108.70M | $44.95M | +80.1% |
| Total operating expense | $491.64M | $290.70M | $159.01M | $87.57M | +69.1% |
| Operating income | -$70.97M | -$120.57M | -$143.16M | -$62.71M | +41.1% |
| Net interest income | $6.81M | $7.17M | $6.99M | $1.30M | -4.9% |
| Pre-tax income | -$64.36M | -$115.55M | -$135.89M | -$62.09M | +44.3% |
| Tax provision | $2.06M | $0 | $0 | -$4.00K | — |
| Net income | -$66.42M | -$115.55M | -$135.89M | -$62.09M | +42.5% |
| Net income to common | -$66.42M | -$115.55M | -$135.89M | -$62.09M | +42.5% |
| Basic EPS | -1.59 | -3.07 | -4.62 | -2.52 | +48.2% |
| Diluted EPS | -1.59 | -3.07 | -4.62 | -2.52 | +48.2% |
| EBIT | -$56.02M | -$108.11M | -$132.67M | -$60.03M | +48.2% |
| EBITDA | -$54.20M | -$106.88M | -$131.79M | -$59.70M | +49.3% |
| Basic shares | 41.78M | 37.60M | 29.38M | 24.62M | +11.1% |
| Diluted shares | 41.78M | 37.60M | 29.38M | 24.62M | +11.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $183.64M | $94.82M | $224.95M | $71.66M | +93.7% |
| Cash & short-term investments | $417.27M | $291.38M | $227.44M | $217.03M | +43.2% |
| Accounts receivable | $85.06M | $46.76M | $16.62M | $0 | +81.9% |
| Inventory | $4.37M | $2.62M | $3.11M | $0 | +66.9% |
| Total current assets | $522.78M | $356.70M | $256.13M | $225.38M | +46.6% |
| Property, plant & equipment | $21.75M | $2.87M | $3.35M | $1.53M | +658.7% |
| Goodwill & intangibles | $7.37M | $8.33M | $3.87M | $0 | -11.5% |
| Total assets | $562.16M | $376.99M | $265.49M | $227.86M | +49.1% |
| Total current liabilities | $135.69M | $80.61M | $36.94M | $15.43M | +68.3% |
| Long-term debt | $72.44M | $71.84M | $29.82M | $19.43M | +0.8% |
| Total debt | $72.44M | $72.45M | $30.22M | $20.16M | -0.0% |
| Total liabilities | $218.73M | $152.46M | $68.50M | $34.96M | +43.5% |
| Retained earnings | -$426.63M | -$360.21M | -$244.66M | -$108.76M | -18.4% |
| Shareholder equity | $343.43M | $224.53M | $196.99M | $192.90M | +53.0% |
| Working capital | $387.09M | $276.09M | $219.19M | $209.95M | +40.2% |
| Net tangible assets | $336.06M | $216.21M | $193.12M | $192.90M | +55.4% |
| Shares issued | 42.55M | 38.35M | 34.21M | 26.73M | +11.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$66.42M | -$115.55M | -$135.89M | -$62.09M | +42.5% |
| Depreciation & amortisation | $1.82M | $1.23M | $877.00K | $326.00K | +48.2% |
| Stock-based compensation | $41.72M | $27.82M | $19.83M | $13.46M | +50.0% |
| Change in working capital | $14.64M | $3.84M | $306.00K | -$951.00K | +280.8% |
| Operating cash flow | -$12.45M | -$83.03M | -$117.49M | -$49.03M | +85.0% |
| Capital expenditure | -$9.86M | -$6.57M | -$5.50M | -$506.00K | -50.1% |
| Investing cash flow | -$42.12M | -$199.19M | $140.60M | -$144.63M | +78.9% |
| Financing cash flow | $143.39M | $154.66M | $130.18M | $93.99M | -7.3% |
| Free cash flow | -$22.31M | -$89.59M | -$123.00M | -$49.54M | +75.1% |
| End cash position | $186.20M | $97.38M | $224.95M | $71.66M | +91.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $173.91M | $162.05M | $151.67M | $118.70M | $102.66M | — | +7.3% |
| Operating revenue | $173.91M | $162.05M | $151.67M | $118.70M | $102.66M | — | +7.3% |
| Cost of revenue | $12.11M | $9.40M | $10.93M | $8.31M | $6.24M | — | +28.9% |
| Gross profit | $161.80M | $152.66M | $140.74M | $110.39M | $96.42M | — | +6.0% |
| Research & development | $31.01M | $22.35M | $18.04M | $16.28M | $15.59M | — | +38.7% |
| Selling, general & admin | $150.70M | $136.43M | $130.68M | $108.63M | $103.01M | — | +10.5% |
| Total operating expense | $181.71M | $158.78M | $148.72M | $124.92M | $118.61M | — | +14.4% |
| Operating income | -$19.91M | -$6.12M | -$7.98M | -$14.53M | -$22.18M | — | -225.2% |
| Net interest income | $1.54M | $1.59M | $1.74M | $1.85M | $1.99M | — | -3.3% |
| Pre-tax income | -$15.84M | -$4.62M | -$6.31M | -$12.59M | -$20.34M | — | -243.1% |
| Tax provision | $2.72M | $2.35M | — | — | $0 | $0 | +15.5% |
| Net income | -$18.55M | -$6.97M | -$8.37M | -$12.59M | -$20.34M | — | -166.3% |
| Net income to common | -$18.55M | -$6.97M | -$8.37M | -$12.59M | -$20.34M | — | -166.3% |
| Basic EPS | -0.43 | -0.16 | -0.20 | -0.30 | -0.48 | — | -168.8% |
| Diluted EPS | -0.43 | -0.16 | -0.20 | -0.30 | -0.48 | — | -168.8% |
| EBIT | -$13.84M | -$2.65M | -$4.26M | -$10.47M | -$18.25M | — | -423.2% |
| EBITDA | -$12.84M | -$2.21M | -$3.81M | -$10.01M | -$17.79M | — | -481.4% |
| Basic shares | 43.39M | 42.96M | 42.78M | 42.61M | 42.36M | — | +1.0% |
| Diluted shares | 43.39M | 42.96M | 42.78M | 42.61M | 42.36M | — | +1.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $204.59M | $102.19M | $183.64M | $112.72M | $96.65M | +100.2% |
| Cash & short-term investments | $449.69M | $388.73M | $417.27M | $401.84M | $381.14M | +15.7% |
| Accounts receivable | $96.03M | $100.34M | $85.06M | $72.62M | $58.33M | -4.3% |
| Inventory | $4.38M | $4.57M | $4.37M | $3.84M | $3.87M | -4.3% |
| Total current assets | $561.99M | $537.23M | $522.78M | $501.70M | $474.43M | +4.6% |
| Property, plant & equipment | $30.40M | $27.67M | $21.75M | $15.98M | $3.41M | +9.9% |
| Goodwill & intangibles | $6.88M | $7.13M | $7.37M | $7.61M | $7.85M | -3.4% |
| Total assets | $611.14M | $581.13M | $562.16M | $534.56M | $494.99M | +5.2% |
| Total current liabilities | $175.75M | $143.51M | $135.69M | $117.05M | $90.25M | +22.5% |
| Long-term debt | $72.76M | $72.60M | $72.44M | $72.28M | $72.13M | +0.2% |
| Total debt | $72.76M | $72.60M | $72.44M | $72.36M | $72.45M | +0.2% |
| Total liabilities | $264.41M | $232.18M | $218.73M | $199.48M | $162.38M | +13.9% |
| Retained earnings | -$452.15M | -$433.60M | -$426.63M | -$418.25M | -$405.67M | -4.3% |
| Shareholder equity | $346.73M | $348.95M | $343.43M | $335.08M | $332.61M | -0.6% |
| Working capital | $386.24M | $393.72M | $387.09M | $384.65M | $384.18M | -1.9% |
| Net tangible assets | $339.85M | $341.82M | $336.06M | $327.48M | $324.77M | -0.6% |
| Shares issued | 43.27M | 43.02M | 42.55M | 42.45M | 42.21M | +0.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$18.55M | -$6.97M | -$8.37M | -$12.59M | -$20.34M | -166.3% |
| Depreciation & amortisation | $1.00M | $437.00K | $443.00K | $460.00K | $453.00K | +128.8% |
| Stock-based compensation | $13.29M | $11.97M | $14.31M | $12.24M | $8.23M | +11.0% |
| Change in working capital | $68.63M | -$29.48M | $13.57M | $19.33M | -$16.36M | +332.8% |
| Operating cash flow | $61.22M | -$24.65M | $19.33M | $18.26M | -$29.39M | +348.3% |
| Capital expenditure | -$4.07M | -$5.82M | -$6.36M | -$1.91M | -$1.00M | +30.1% |
| Investing cash flow | $37.88M | -$58.56M | $49.27M | -$4.74M | -$51.70M | +164.7% |
| Financing cash flow | $3.30M | $1.20M | $2.31M | $2.56M | $1.95M | +174.3% |
| Free cash flow | $57.15M | -$30.47M | $12.97M | $16.35M | -$30.39M | +287.6% |
| End cash position | $206.60M | $104.19M | $186.20M | $115.29M | $99.21M | +98.3% |
Options analytics
Put / call volume
0.67
Call-heavy session
Put / call open interest
0.80
Positioning, not flow
Max pain
40.00
-46.0% from spot
ATM implied vol
1.6%
Nearest strike to spot
Skew (10% OTM)
+12.5%
Puts bid over calls
Call volume
36
Contracts, this expiry
Put volume
24
Contracts, this expiry
Heaviest call OI
55.00
4 contracts
Heaviest put OI
40.00
2 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.20 | -0.43 | -119.4% |
| Mar 2026 | -0.42 | -0.16 | +62.1% |
| Dec 2025 | 0.01 | -0.20 | -1,974.4% |
| Sep 2025 | -0.33 | -0.30 | +9.1% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -1.77 | 3 | $183.63M | +54.7% |
| Next quarter | -3.39 | 3 | $201.45M | +32.8% |
| Current year | -5.77 | 3 | $721.05M | +59.8% |
| Next year | -0.36 | 2 | $927.25M | +28.6% |
Analyst targets & ownership
Mean target$99.50
High target$116.00
Low target$84.00
Implied upside32.35%
Analyst count10
ConsensusSTRONG BUY
Strong buy / Buy1 / 9
Hold0
Sell / Strong sell0 / 0
Held by insiders2.69%
Held by institutions99.93%
Institutions holding358
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
75.51
-0.43% from price
SMA 20
77.29
-4.11% from price
SMA 50
73.02
+1.49% from price
SMA 100
67.25
+11.80% from price
SMA 200
68.50
+8.18% from price
EMA 12
75.82
-0.84% from price
EMA 26
75.81
-0.83% from price
EMA 50
73.49
+2.30% from price
RSI (14)
46.1
Neutral
MACD (12,26,9)
0.01
Hist -0.83
ATR (14)
2.64
3.56% of price
Realised vol 30D
53.6%
Annualised
Bollinger upper
82.11
20, 2σ
Bollinger lower
72.47
20, 2σ
50 / 200 cross
Golden
73.02 vs 68.50
Trend bias
Above 200
+8.18%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.59
Less volatile than market
Correlation to SPY
0.17
Largely independent
Realised vol 30D
53.6%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-32.0%
Peak to trough
Max drawdown 5Y
-62.7%
Peak to trough
ATR 14
2.64
3.56% of price
Beta (reported)
0.45
5Y monthly, from filing
Short interest
Shares short
6.13M
Prior 6.00M
Change vs prior
+2.2%
Shorts adding
% of float
13.50%
Elevated
% of shares out
13.10%
Against total outstanding
Days to cover
7.9
Crowded exit
Float
32.74M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 8, 26 | Jefferies | MAINTAINED | Buy | Buy |
| Aug 12, 26 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| Jul 31, 26 | Mizuho | MAINTAINED | Outperform | Outperform |
| Jul 21, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Jul 9, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 4, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 25, 26 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| Feb 25, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Dec 9, 25 | Barclays | INITIATED | — | Overweight |
| Nov 20, 25 | Mizuho | INITIATED | — | Outperform |
| Nov 5, 25 | Guggenheim | MAINTAINED | Buy | Buy |
| Oct 20, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-10
Corporate Changes & Voting Matters
8-K · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-07-13
Corporate Changes & Voting Matters
8-K · 2026-07-08
Corporate Changes & Voting Matters
8-K · 2026-06-29
Periodic Financial Reports
10-Q · 2026-05-06
Proxy Statements
DEFA14A · 2026-04-28
Corporate Changes & Voting Matters
8-K · 2026-02-23
Headlines
Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting
GlobeNewswire · 8d ago
When To Dump Stocks: These IBD 50 Components Hit Sell Signals
Investor's Business Daily · 19d ago
Tarsus Pharmaceuticals Insider Sold Shares Worth $979,744, According to a Recent SEC Filing
MT Newswires · 19d ago
Tarsus Pharmaceuticals Insider Sold Shares Worth $387,940, According to a Recent SEC Filing
MT Newswires · 27d ago
Tarsus Pharmaceuticals Insider Sold Shares Worth $1,220,885, According to a Recent SEC Filing
MT Newswires · 27d ago
Update: Tarsus Pharmaceuticals Shares Rise After Closing Alkeus Pharmaceuticals Acquisition
MT Newswires · 32d ago
Tarsus Pharmaceuticals Closes Acquisition of Alkeus Pharmaceuticals
MT Newswires · 33d ago
Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care
GlobeNewswire · 33d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.